{"id":231362,"date":"2026-02-14T17:07:48","date_gmt":"2026-02-14T23:07:48","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/02\/evaluation-of-preexisting-humoral-immunity-to-measles-and-varicella-zoster-in-patients-with-multiple-sclerosis-initiating-anti-cd20-therapy"},"modified":"2026-02-14T17:07:48","modified_gmt":"2026-02-14T23:07:48","slug":"evaluation-of-preexisting-humoral-immunity-to-measles-and-varicella-zoster-in-patients-with-multiple-sclerosis-initiating-anti-cd20-therapy","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/02\/evaluation-of-preexisting-humoral-immunity-to-measles-and-varicella-zoster-in-patients-with-multiple-sclerosis-initiating-anti-cd20-therapy","title":{"rendered":"Evaluation of Preexisting Humoral Immunity to Measles and Varicella Zoster in Patients With Multiple Sclerosis Initiating Anti-CD20 Therapy"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/evaluation-of-preexisting-humoral-immunity-to-measles-and-varicella-zoster-in-patients-with-multiple-sclerosis-initiating-anti-cd20-therapy2.jpg\"><\/a><\/p>\n<p>This case report describes mogamulizumab-associated Kaposi sarcoma in 2 patients with primary cutaneous T-cell lymphomas.<\/p>\n<p>\ud83d\udcc4Read the full report.<\/p>\n<hr>\n<p>\n<strong>Corresponding Author:<\/strong> Emilie Holder, MD, Service de Dermatologie, Hospices Civils de Lyon, H\u00f4pital Lyon Sud, F-69495 Oullins-Pierre-B\u00e9nite, France (<a href=\"mailto:emilie-nadia.holder@chru-strasbourg.fr\" target=\"_blank\">emilie-nadia.holder@chru-strasbourg.fr<\/a>).<\/p>\n<p><strong>Published Online:<\/strong> February 11, 2026. doi:10.1001\/jamadermatol.2025.<\/p>\n<p><strong>Conflict of Interest Disclosures:<\/strong> Dr Dalle reported grants from Bristol Myers Squibb, Merck Sharp &amp; Dohme, Pierre Fabre, and Regeneron, and his spouse is an employee of Sanofi outside the submitted work. No other disclosures were reported.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This case report describes mogamulizumab-associated Kaposi sarcoma in 2 patients with primary cutaneous T-cell lymphomas. \ud83d\udcc4Read the full report. Corresponding Author: Emilie Holder, MD, Service de Dermatologie, Hospices Civils de Lyon, H\u00f4pital Lyon Sud, F-69495 Oullins-Pierre-B\u00e9nite, France (emilie-nadia.holder@chru-strasbourg.fr). Published Online: February 11, 2026. doi:10.1001\/jamadermatol.2025. Conflict of Interest Disclosures: Dr Dalle reported grants from Bristol Myers [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-231362","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/231362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=231362"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/231362\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=231362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=231362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=231362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}